Point72 Asia (Singapore) Pte. Ltd. Atea Pharmaceuticals, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $384 Billion
- Q1 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 5,500 shares of AVIR stock, worth $17,875. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,500Holding current value
$17,875% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding AVIR
# of Institutions
119Shares Held
49.6MCall Options Held
108KPut Options Held
327K-
Black Rock Inc. New York, NY9.24MShares$30 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.15MShares$20 Million0.71% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.54MShares$18 Million14.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$15.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.08MShares$13.2 Million2.01% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $271M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...